ASPARLAS: payments to doctors
Payments that named ASPARLAS as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $638K
- Providers
- 981
- Transactions
- 1,969
- Average per transaction
- $324
The per-transaction average — $324 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 981 providers the average total is $650, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Servier Pharmaceuticals LLC | $601,646 | 94.3% |
| Servier Bioinnovation | $28,840 | 4.5% |
| Servier Affaires Medicales | $4,938 | 0.8% |
| Institut De Recherches Internationales Servier | $2,640 | 0.4% |